Build an Inve Case for NBP → Read the full call →
NovaBridge Biosciences (NBP) earnings
NovaBridge Biosciences earnings: last reported Thu, 20 Aug 2026, for the quarter ended Jun 2026.
NovaBridge Biosciences earnings callsNovaBridge Biosciences earnings calls (NBP)
Latest concall · Q2 2026 · call held call held 20 Aug 2026
NovaBridge Biosciences H1 FY26 — Strategic Focus on Oncology and Ophthalmology Pipeline Advancement
What went well
- Reported $216 million in cash and investments as of June 30, 2026, providing meaningful financial flexibility.
- Givastomig granted Fast Track designation by the FDA in June 2026, increasing confidence in its development pathway.
- Givastomig Phase Ib data showed a 75% overall response rate (ORR) and a preliminary median progression-free survival (PFS) of 16.9 months in first-line gastric cancer.
Performance −59.9% 1Y
1Y: $3.42 on 29 Sept 2025 → $1.37. High $6.56 (16 Oct 2025), low $1.36 (28 Sept 2026).
Balance sheet
| Year ending | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | $17.0K | $20.0K | $19.0K | $19.0K | $19.0K | $27.0K |
| Reserves | -$310.08M | -$683.37M | -$994.92M | -$1.26B | -$1.29B | -$1.33B |
| Total liabilities | $108.30M | $163.45M | $168.73M | $126.34M | $11.52M | $29.58M |
| Fixed assets | $3.87M | $7.17M | $8.82M | $1.78M | $201.0K | $140.0K |
| Investments | $4.83M | $118.19M | $34.13M | $20.22M | $105.14M | $210.0K |
| Total assets | $970.70M | $878.95M | $590.63M | $368.92M | $212.68M | $260.52M |
How to read this
As filed on each reporting date, including interim balance sheets. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Insider filings
16 filings between Apr 24, 2026 and Sep 18, 2026.
Open market
decisions to buy or sellPurchases
$577.3K
1 purchase by 1 insider
Sales
$154.3K
7 sales by 3 insiders
Compensation
not trading decisions- 8
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Hagler Mark Arnold | $577.3K | — | Apr 24, 2026 |
| Cao Sean Wuxiong | — | $122.5K | Sep 9, 2026 |
| Xu Cong Claire | — | $20.4K | Aug 31, 2026 |
| Dennis Phillip Andrew | — | $11.4K | Sep 18, 2026 |
Latest filings (16)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 18, 2026 | Dennis Phillip Andrew Chief Medical Officer | Sale | 8,209 | $5.8K |
| Sep 17, 2026 | Dennis Phillip Andrew Chief Medical Officer | Option exercise | 23,695 | — |
| Sep 9, 2026 | Cao Sean Wuxiong Chief Bus. Development Officer | Sale | 107,978 | $79.9K |
| Sep 3, 2026 | Cao Sean Wuxiong Chief Bus. Development Officer | Option exercise | 104,236 | — |
| Sep 3, 2026 | Cao Sean Wuxiong Chief Bus. Development Officer | Option exercise | 235,136 | — |
| Aug 31, 2026 | Xu Cong Claire EVP, Clinical Development | Sale | 3,282 | $2.6K |
| Aug 30, 2026 | Xu Cong Claire EVP, Clinical Development | Option exercise | 9,382 | — |
| Aug 22, 2026 | Lenz Robert A. Director | Option exercise | 17,218 | — |
| Jul 6, 2026 | Xu Cong Claire SVP, Clinical Development | Sale | 4,485 | $4.0K |
| Jul 4, 2026 | Xu Cong Claire SVP, Clinical Development | Option exercise | 12,432 | — |
| Jun 18, 2026 | Dennis Phillip Andrew Chief Medical Officer | Sale | 8,494 | $5.6K |
| Jun 17, 2026 | Dennis Phillip Andrew Chief Medical Officer | Option exercise | 23,695 | — |
| Jun 1, 2026 | Xu Cong Claire SVP, Clinical Development | Sale | 3,494 | $13.8K |
| May 30, 2026 | Xu Cong Claire SVP, Clinical Development | Option exercise | 9,382 | — |
| May 14, 2026 | Cao Sean Wuxiong See Remarks | Sale | 21,399 | $42.6K |
| Apr 24, 2026 | Hagler Mark Arnold See Remarks | Purchase | 230,000 | $577.3K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.